ArticleProceedings of the National Academy of Sciences of the United States of America1991
Positive selection of candidate tumor-suppressor genes by subtractive hybridization.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 318 citations in OpenAlex.
- The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours.Journal of cellular and molecular medicine · 2025Article
- Review of electrophysiological models to study membrane potential changes in breast cancer cell transformation and tumor progression.Frontiers in physiology · 2025Review
- Integrative analyses identified gap junction beta-2 as a prognostic biomarker and therapeutic target for breast cancer.Cancer innovation · 2024Article
- Targeting NANOG and FAK via Cx26-derived Cell-penetrating Peptides in Triple-negative Breast Cancer.Molecular cancer therapeutics · 2024Article
- Pathogenic role of S100 proteins in psoriasis.Frontiers in immunology · 2023Review
- White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy.Cancers · 2022Article
- ITIH5-Derived Polypeptides Covering the VIT Domain Suppress the Growth of Human Cancer Cells In Vitro.Cancers · 2022Article
- The role of connexins in breast cancer: from misregulated cell communication to aberrant intracellular signaling.Tissue barriers · 2022Review
- Trace elements and oxidative stress status in patients with psoriasis.Postepy dermatologii i alergologii · 2020Article
- Progress in the application of organoids to breast cancer research.Journal of cellular and molecular medicine · 2020Review
- Direct Intercellular Communications and Cancer: A Snapshot of the Biological Roles of Connexins in Prostate Cancer.Cancers · 2019Review
- Prognostic values of S100 family members in ovarian cancer patients.BMC cancer · 2018Article
- Connexin 26 Expression in Mammalian Cardiomyocytes.Scientific reports · 2018Article
- Cancer Connectors: Connexins, Gap Junctions, and Communication.Frontiers in oncology · 2018Review
- Connexin's Connection in Breast Cancer Growth and Progression.International journal of cell biology · 2016Review
- Possible role of hemichannels in cancer.Frontiers in physiology · 2014Article
- Intercellular redistribution of cAMP underlies selective suppression of cancer cell growth by connexin26.PloS one · 2013Article
- S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma.Gene therapy · 2012Article
- Isolation and analysis of genes mainly expressed in adult mouse heart using subtractive hybridization cDNA library.Molecular biology reports · 2012Article
- Cx43 suppresses mammary tumor metastasis to the lung in a Cx43 mutant mouse model of human disease.Oncogene · 2011Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A positive selection system designed to identify and recover candidate tumor-suppressor genes is described. The system compares mRNA expression of genes from normal and tumor-derived human mammary epithelial cells grown in a special medium that supports similar growth rates of the two cell types. mRNAs uniquely expressed in normal cells are recovered as cDNAs after subtraction with mRNA from tumor cells. Seven different clones, from 0.6 to 4.8 kilobases in transcript size and including both rare and abundunt transcripts, were recovered in the first 23 clones analyzed. Among the isolated clones were genes encoding the gap-junction protein connexin 26, two different keratins, and glutathione-S-transferase pi, as well as an unknown gene in the S100 family of small calcium-binding proteins. In principle, tumor-suppressor genes include two classes: class I, in which loss of function results from mutation or deletion of DNA and class II, in which loss of function is from a regulatory block to expression. A class II suppressor gene is assumed to be regulated by a different suppressor gene that lost its function by mutation or deletion. Both classes of tumor-suppressor genes may provide valuable proteins with clinical applications in cancer diagnosis or therapy. Class II suppressors may be especially useful because the normal genes are present and their reexpression may be inducible by drugs or other treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.